At EMD Serono, Regina works to develop, optimize, and execute various cellular screening assays for targets in oncology and also, in the near future, neurodegenerative diseases. This involves evaluating lead and hit-to-lead small molecules and antibody-based therapeutics for modulation of cell signaling pathways, cell cycle, proliferation, viability, and mechanism of death.
Regina joined EMD Serono because the company offers its employees the opportunity to perform purposeful, clinically relevant work. She finds it rewarding to be part of an organization that truly values its employees.
Regina is proud of the support she provided for EMD Serono’s MEK inhibitor, which is now in clinical trials. While working on this project, she screened small molecules and helped characterize the cellular pharmacology of the inhibitors.
University of Rhode Island. B.S., Biological Sciences (2001)
University of Rhode Island. M.S., Biological Sciences (2003)
Webster B, Ekland EH, Agle LM, Chyou S, Ruggieri R,, Lu TT. Lymph node microvasculature proliferation is modulated by dendritic cells during the immune response. J Exp Med. 2006 Aug 7;203(8):1903-1913.
Ruggieri RD, Pierobon P, Kass-Simon G. Pacemaker activity in hydra is modulated by glycine receptor ligands. Comp. Biochem. Physiol A Mol Integr Physiol. 2004 Jun;138(2):193-202.
Regina’s experiences with cancer in her personal life have given her acute awareness of the significance and urgency of her work at EMD Serono to develop novel targeted and effective oncology drugs. Despite many advances over the years, there are still many unmet medical needs when it comes to cancer therapies. Cancer patients need drugs that specifically target their cancers with minimal detrimental effects on healthy tissues. Regina believes that EMD Serono has an important role to play in combating cancers because of its commitment to attracting and retaining talented chemists and biologists and its ability to provide them with the resources to do good scientific work.